<DOC>
	<DOCNO>NCT01047007</DOCNO>
	<brief_summary>The study evaluate safety MK1775 monotherapy , combination 5-FU alone 5-FU/CDDP Japanese patient solid tumor</brief_summary>
	<brief_title>A Dose Escalation Study MK1775 Combination With 5-FU 5-FU/CDDP Patients With Advanced Solid Tumor ( 1775-005 )</brief_title>
	<detailed_description />
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Parts 1 2A : Patient must histologically cytologically confirm locally advanced metastatic solid tumor fail respond standard therapy , progress despite standard therapy , standard therapy exist Parts 2B 3 : Patient must histologically cytologically confirm locally advanced metastatic esophageal , head neck , gastric cancer , candidate 5Fluorouracil Cisplatin regimen define study Patient must performance status 0 1 ECOG Performance Scale Patient chemotherapy , radiotherapy , biological therapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior first dose study drug recover adverse event due agent administer 4 week earlier Patient know primary central nervous system tumor Patient know hypersensitivity component combination study therapy analog Patient receive `` alternative '' cancer medication plantderived product analogs antitumor activity within 1 week prior enter study . Patient must prior radiation therapy 30 % bone marrow must recover least 3 week hematologic toxicity prior radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Esophageal Cancer</keyword>
	<keyword>Gastric Cancer</keyword>
</DOC>